Ligand Pharmaceuticals to Announce Q2 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has made an exciting announcement regarding its upcoming financial results. The company is set to report its second-quarter financial results soon, with the specific date confirmed for August 7, 2025.
Conference Call Details
As part of this announcement, Ligand will host a conference call to discuss the financial results and provide a broader update on its business activities. The call is scheduled to begin at 8:30 a.m. ET on the date of the financial report.
How to Join the Call
Investors and analysts can participate in the conference call by dialing either of the following numbers:
- (800) 715-9871 for U.S. and Canada callers
- (646) 307-1963 for international participants
For convenience, those joining the call will need to use Conference ID number 3661098.
Webcast Availability
Additionally, the conference call will be accessible via a live webcast. This will allow participants to listen online, enhancing accessibility for all interested parties. The recorded version will also be available later for those who cannot join the live session.
A Glimpse into Ligand Pharmaceuticals
Ligand Pharmaceuticals is a prominent biopharmaceutical company dedicated to fostering scientific progress. The company has made a name for itself in the industry by actively supporting the clinical development of a range of high-value medicines. To achieve this, Ligand employs a business model that provides both financing and licensing of its groundbreaking technologies.
Business Model Insights
Ligand’s operational strategy focuses on generating shareholder value through a diverse portfolio of revenue streams derived from biotechnology and pharmaceuticals. By maintaining a low corporate cost structure, Ligand aims to give investors a unique opportunity to engage with the biotechnology sector's promising future successfully. The company's approach includes funding mid- to late-stage drug development projects, acquiring royalty rights in emerging biopharmaceutical products, and licensing their proprietary technologies to enhance efficient drug discovery processes.
Strategic Partnerships
To further bolstering its revenue, Ligand collaborates with leading pharmaceutical companies, maximizing their strengths in late-stage development, regulatory management, and commercialization. This collaborative approach contributes significantly to the company’s ongoing success.
Technological Innovations by Ligand
Ligand leverages two innovative platform technologies that are core to its operations: Captisol® and NITRICIL™. The Captisol® technology is a chemically modified cyclodextrin that enhances drug stability and solubility, whereas NITRICIL™ offers adjustable drug release profiles, allowing for a tailored approach to various medical conditions.
Notable Partnerships
The company's significant partnerships include collaborations with top-tier firms such as Amgen, Merck, and Pfizer, which amplify its capacity to innovate and expand its product offerings. These alliances are integral in ensuring Ligand remains at the forefront of pharmaceutical advancements.
Staying Informed with Ligand Pharmaceuticals
Investors are encouraged to keep abreast of Ligand’s developments through their investor relations website. Furthermore, Ligand actively discloses important non-public information via this platform, aligning with the regulatory requirements to keep the investment community informed.
Connect with Ligand Pharmaceuticals
For any inquiries, investors can reach out to the company directly. The contact details are as follows:
Investors:
Melanie Herman
Email: investors@ligand.com
Phone: (858) 550-7761
Frequently Asked Questions
When will Ligand report its Q2 financial results?
Ligand is scheduled to report its Q2 financial results on August 7, 2025.
How can I participate in the Q2 results conference call?
You can join the conference call by calling (800) 715-9871 for U.S. participants or (646) 307-1963 for international participants.
Will there be a webcast for the conference call?
Yes, a live webcast will be available for those who wish to join online.
What technologies does Ligand Pharmaceuticals specialize in?
Ligand focuses on Captisol® and NITRICIL™ technologies to enhance drug development and delivery.
Who can I contact for more information about Ligand?
You can reach out to Melanie Herman at investors@ligand.com for investor inquiries.
